Published in Contrib Nephrol on May 03, 2013
Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci (2014) 0.79
Mitochondrial functional impairment in response to environmental toxins in the cardiorenal metabolic syndrome. Arch Toxicol (2015) 0.75
Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. Biochim Biophys Acta (2016) 0.75
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Body weight and mortality among women. N Engl J Med (1995) 11.04
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
The lifetime risk of stroke: estimates from the Framingham Study. Stroke (2006) 4.68
Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med (2007) 3.97
Obesity and risk for chronic renal failure. J Am Soc Nephrol (2006) 3.67
Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ (2012) 3.22
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int (2006) 3.00
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc Imaging (2010) 2.69
Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA (1988) 2.68
Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol (1991) 2.56
Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci (2001) 2.54
Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol (2009) 2.20
Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int (2003) 2.04
Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke (2010) 1.87
Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology (2006) 1.65
From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis (2009) 1.49
Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study. Nephrol Dial Transplant (2007) 1.47
Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res (2011) 1.40
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail (2007) 1.23
Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta (2011) 1.12
Predictors of severe stroke: influence of preexisting dementia and cardiac disorders. Stroke (2002) 1.09
Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail (2011) 1.05
Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data. Circ Cardiovasc Qual Outcomes (2010) 0.97
Impact of body mass index on left ventricular diastolic dysfunction. Echocardiography (2012) 0.83
Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis (2012) 0.83
Left ventricular morphology and diastolic function in severe obesity: current views. Rev Esp Cardiol (Engl Ed) (2011) 0.77
Metformin: an update. Ann Intern Med (2002) 5.62
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol (2004) 1.73
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc (2006) 1.60
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) (2008) 1.50
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Epidemiology of diabetes. J Clin Pharmacol (2004) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol (2007) 1.39
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
The metabolic syndrome: role of skeletal muscle metabolism. Ann Med (2006) 1.28
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med (2011) 1.23
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol (2008) 1.16
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.16
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2008) 1.12
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol (2008) 1.11
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Hypertension in obesity. Med Clin North Am (2011) 1.10
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol (2003) 1.09
Heart disease in diabetic patients. Curr Diab Rep (2003) 1.09
Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin (2012) 1.07
The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) (2013) 1.06
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol (2008) 1.06
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal (2007) 1.05
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol (2014) 1.04
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol (2009) 1.02
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis (2006) 1.01
Stroke in patients with diabetes and hypertension. J Clin Hypertens (Greenwich) (2005) 1.01
Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction. Am J Physiol Heart Circ Physiol (2012) 1.01
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol (2007) 1.01
Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep (2014) 1.01